Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Repurchased
Ratios

Xeris Biopharma Holdings (XERS) Accumulated Depreciation & Amortization (2020 - 2025)

Historic Accumulated Depreciation & Amortization for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $978000.0.

  • Xeris Biopharma Holdings' Accumulated Depreciation & Amortization rose 700.22% to $978000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $978000.0, marking a year-over-year increase of 700.22%. This contributed to the annual value of $1.2 million for FY2024, which is 1820.0% down from last year.
  • Xeris Biopharma Holdings' Accumulated Depreciation & Amortization amounted to $978000.0 in Q3 2025, which was up 700.22% from $640000.0 recorded in Q2 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Accumulated Depreciation & Amortization peaked at $1.5 million during Q4 2023, and registered a low of $315000.0 during Q1 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' median Accumulated Depreciation & Amortization value was $750000.0 (recorded in 2023), while the average stood at $815368.4.
  • In the last 5 years, Xeris Biopharma Holdings' Accumulated Depreciation & Amortization skyrocketed by 1339.56% in 2023 and then plummeted by 1989.48% in 2024.
  • Xeris Biopharma Holdings' Accumulated Depreciation & Amortization (Quarter) stood at $1.3 million in 2021, then increased by 5.34% to $1.4 million in 2022, then grew by 7.14% to $1.5 million in 2023, then fell by 18.2% to $1.2 million in 2024, then dropped by 20.29% to $978000.0 in 2025.
  • Its Accumulated Depreciation & Amortization was $978000.0 in Q3 2025, compared to $640000.0 in Q2 2025 and $315000.0 in Q1 2025.